Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and Disbacteriosis

irinotecan has been researched along with Disbacteriosis in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Abu, YF; Chen, C; Meng, J; Ramakrishnan, S; Roy, S; Tao, J; Xie, Y; Yan, Y; Zhang, Y; Zhou, Y1
Azcarate-Peril, MA; Bailey, ST; Bhatt, AP; Biernat, KA; Bultman, SJ; Creekmore, BC; Darr, DB; Gharaibeh, RZ; Letertre, MM; Montgomery, SA; Pellock, SJ; Redinbo, MR; Roach, JM; Roques, JR; Sartor, RB; Swann, JR; Wallace, BD; Walton, WG; Wilson, ID1
Chen, YY; Duan, JA; Jiang, JQ; Kang, A; Qin, YF; Tang, YP; Tao, HJ; Yue, SJ; Zhou, GS1
Chen, S; Feng, M; Guo, S; Hou, Q; Liu, Y; Pan, Y; Sun, L; Wang, P; Wang, Y; Xu, H; Yue, T1

Other Studies

4 other study(ies) available for irinotecan and Disbacteriosis

ArticleYear
Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model.
    British journal of pharmacology, 2023, Volume: 180, Issue:10

    Topics: Analgesics, Opioid; Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Disease Models, Animal; Dysbiosis; Glucuronidase; Humans; Irinotecan; Male; Mice; Mice, Inbred C57BL; Morphine Derivatives; Neoplasms; RNA, Ribosomal, 16S

2023
Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 03-31, Volume: 117, Issue:13

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Disease Models, Animal; Dysbiosis; Enzyme Inhibitors; Female; Gastrointestinal Microbiome; Glucuronidase; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms

2020
Total Flavonoids of
    Frontiers in immunology, 2021, Volume: 12

    Topics: Animals; Anti-Inflammatory Agents; Bacteria; Colitis; Colon; Cytokines; Disease Models, Animal; Dysbiosis; Feces; Flavonoids; Gastrointestinal Microbiome; Glycyrrhiza uralensis; Inflammasomes; Inflammation Mediators; Irinotecan; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Plant Extracts

2021
The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice.
    Life sciences, 2019, Aug-15, Volume: 231

    Topics: Animals; Caco-2 Cells; Claudin-1; Diarrhea; Dysbiosis; Escherichia coli; Gastrointestinal Diseases; Gastrointestinal Microbiome; Humans; Intestinal Diseases; Intestinal Mucosa; Intestines; Irinotecan; Male; Mice; Mice, Inbred BALB C; Probiotics; Tight Junction Proteins

2019